The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...
Heart doctors are capturing images of the inside of heart arteries, helping them watch plaque respond to cholesterol drugs in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback